	US 11,730,777 B2
	Mucoadhesive sustained-release vaginal tablet
Claudia Thoral, Massiac (FR); Pierre Tchoreloff, Gradignan (FR); Vincent Mazel, Mérignac (FR); Virginie Busignies, Mérignac (FR); and Adrien Nivoliez, Yolet (FR)
Assigned to NEXBIOME THERAPEUTICS, Clermont-Ferrand (FR)
Filed by BIOSE, Arpajon-sur-Cere (FR)
Filed on Jun. 25, 2019, as Appl. No. 16/451,881.
Application 16/451,881 is a continuation of application No. 15/124,148, abandoned, previously published as PCT/EP2015/054918, filed on Mar. 10, 2015.
Claims priority of application No. 1451951 (FR), filed on Mar. 10, 2014.
Prior Publication US 2020/0155621 A1, May 21, 2020
Int. Cl. A61K 35/747 (2015.01); A61K 9/00 (2006.01); A61K 9/20 (2006.01); A61K 9/02 (2006.01)

CPC A61K 35/747 (2013.01) [A61K 9/0034 (2013.01); A61K 9/02 (2013.01); A61K 9/2054 (2013.01)]

5 Claims

1. A mucoadhesive sustained-release vaginal tablet consisting essentially of: from 10⁹to 10¹¹CFU of Lactobacillus rhamnosus Lcr35 per gram of tablet; and an excipient that is 10% to 30% by weight of the tablet relative to the total weight of the tablet, is suitable for conferring upon said tablet its properties of vaginal wall mucoadhesion and sustained release, and is hydroxypropylmethylcellulose with a dynamic viscosity greater than 10,000 mPa·s, wherein formation of the tablet comprises subjecting the Lactobacillus rhamnosus Lcr35 and said excipient to a compressive stress of from 50 to 400 MPa, resulting in maintenance of viability and sustained release of the Lactobacillus rhamnosus Lcr35 from the tablet and in the vaginal muco-adhesion of the tablet.